Suggested remit: to appraise the clinical and cost effectiveness of pembrolizumab with chemoradiation within its marketing authorisation for untreated high-risk locally advanced cervical cancer.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6138
Provisional Schedule
- Expected publication:
- 15 October 2025
Project Team
- Project lead
- Jennifer Upton
Email enquiries
If you have any queries please email [email protected]
- External Assessment Group:
- Southampton Health Technology Assessment Centre (SHTAC), University of Southampton
Stakeholders
- Companies sponsors
- Merck Sharp & Dohme (pembrolizumab)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- None
- Professional groups
- Association of Cancer Physicians
- British Gynaecological Cancer Society
- Cancer Research UK
- Royal College of Physicians
- Royal College of Radiologists
- Associated public health groups
- None
- Comparator companies
- None
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health, Social Services and Public Safety for Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- Scottish Medicines Consortium
- Welsh Government
- NHS Wales Joint Commissioning Committee
- Relevant research groups
- Institute of Cancer Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 05 August 2025 | Committee meeting |
| 06 January 2025 | Invitation to participate |
| 09 December 2024 - 23 December 2024 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 28 March 2024 | Please note that following conversations between NICE and the company this topic has been scheduled into the work programme. The appraisal is now anticipated to begin will begin during early January 2025 when we will write to you about how you can get involved. |
| 28 December 2023 | Please note that following on from advice received from the company, further information regarding the timelines for this appraisal will be available in due course. In the meantime, NICE will continue to monitor the situation and will provide an update as and when the situation changes. |
| 22 November 2023 - 20 December 2023 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6138 |
| 28 June 2023 | Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during mid-January 2024 when we will write to stakeholders about how they can get involved. The deadline for submissions is expected in approximately mid-March 2024. |
| 01 February 2023 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
| 29 November 2022 | As you will be aware, the Department for Health & Social Care has asked NICE to conduct an appraisal of Pembrolizumab with chemoradiation within its marketing authorisation for untreated high-risk advanced cervical cancer. Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin in late October 2023 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately mid-January 2024. |
| 13 October 2022 | In progress. DHSC referral received |
For further information on our processes and methods, please see our CHTE processes and methods manual